PL2663580T3 - Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem - Google Patents

Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem

Info

Publication number: PL2663580T3
Authority: PL; Poland
Prior art keywords: antigen binding; combination therapy; associated antigen; tumor associated; binding antibodies
Prior art date: 2011-01-10

Application number

PL12701463T

Other languages

English (en)

Inventor

Christoph Esslinger

Alexander Knuth

Martin Treder

Den Broek Maries Van

Elke Jaeger

Original Assignee

Ct Atlantic Ltd.

Universität Zürich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-10

Filing date

2012-01-10

Publication date

2017-08-31

2012-01-10 Application filed by Ct Atlantic Ltd., Universität Zürich filed Critical Ct Atlantic Ltd.

2017-08-31 Publication of PL2663580T3 publication Critical patent/PL2663580T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL12701463T 2011-01-10 2012-01-10 Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem PL2663580T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11150527		2011-01-10
EP12701463.7A EP2663580B1 (en)	2011-01-10	2012-01-10	Combination therapy including tumor associated antigen binding antibodies

Publications (1)

Publication Number	Publication Date
PL2663580T3 true PL2663580T3 (pl)	2017-08-31

Family

ID=43827681

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12701463T PL2663580T3 (pl)	2011-01-10	2012-01-10	Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem

Country Status (13)

Country	Link
US (2)	US20130295091A1 (pl)
EP (1)	EP2663580B1 (pl)
JP (1)	JP5828909B2 (pl)
KR (1)	KR101614997B1 (pl)
CN (1)	CN103347898B (pl)
CA (1)	CA2821117C (pl)
DK (1)	DK2663580T3 (pl)
ES (1)	ES2617983T3 (pl)
HU (1)	HUE031197T2 (pl)
IL (1)	IL226675A0 (pl)
PL (1)	PL2663580T3 (pl)
PT (1)	PT2663580T (pl)
WO (1)	WO2012095412A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX349057B (es)	2010-11-30	2017-07-07	Chugai Pharmaceutical Co Ltd	Agente terapeutico que induce citotoxicidad.
EA032326B1 (ru)	2013-04-18	2019-05-31	Иммьюн Дизайн Корп.	Монотерапия gla для применения в лечении рака
GB201311487D0 (en) *	2013-06-27	2013-08-14	Alligator Bioscience Ab	Bispecific molecules
MY194892A (en) *	2014-04-07	2022-12-22	Chugai Pharmaceutical Co Ltd	Immunoactivating antigen-binding molecule
CN106459954A (zh)	2014-05-13	2017-02-22	中外制药株式会社	用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
GB201413665D0 (en)	2014-07-03	2014-09-17	Transimmune Ag And Yale University	Method for obtaining globally activated monocytes
EP3242890B1 (en) *	2015-01-08	2019-09-04	BioNTech SE	Agonistic tnf receptor binding agents
CN104830796A (zh) *	2015-05-05	2015-08-12	杨光华	基于spanxa1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
CN115109158A (zh)	2015-05-07	2022-09-27	阿吉纳斯公司	抗ox40抗体及其使用方法
KR101652643B1 (ko) *	2015-07-03	2016-08-30	서울과학기술대학교 산학협력단	줄로리딘계 화합물, 이를 이용한 알루미늄 이온 검출제, 검출방법 및 검출장치
WO2017086367A1 (ja)	2015-11-18	2017-05-26	中外製薬株式会社	免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en)	2015-11-18	2023-05-16	Chugai Seiyaku Kabushiki Kaisha	Method for enhancing humoral immune response
TW202134282A (zh)	2015-12-02	2021-09-16	美商艾吉納斯公司	抗體和使用彼之方法
GB201604490D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
RU2018139339A (ru) *	2016-04-22	2020-05-22	Эллигейтор Биосайенс Аб	Новые биспецифические полипептиды против cd137
CA3041340A1 (en)	2016-11-09	2018-05-17	Agenus Inc.	Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US20190336615A1 (en) *	2017-01-27	2019-11-07	Silverback Therapeutics, Inc.	Tumor targeting conjugates and methods of use thereof
US11866785B2 (en)	2017-10-27	2024-01-09	Board Of Regents, The University Of Texas System	Tumor specific antibodies and T-cell receptors and methods of identifying the same
CN108624566B (zh) *	2018-05-15	2021-06-01	广东医科大学	一种抗ct83蛋白单克隆抗体及杂交瘤细胞株
CN110687283B (zh) *	2019-08-26	2023-05-23	中国医学科学院肿瘤医院	自身抗体在诊断和/或治疗肿瘤中的应用
WO2021168274A1 (en)	2020-02-21	2021-08-26	Silverback Therapeutics, Inc.	Nectin-4 antibody conjugates and uses thereof
KR20230047361A (ko)	2020-07-01	2023-04-07	아르스 파마슈티컬스 인크.	항-asgr1 항체 접합체 및 이의 용도
TW202511286A (zh) *	2023-07-25	2025-03-16	大陸商上海筠璇生物科技有限公司	抗體及其應用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6252052B1 (en)	1996-10-03	2001-06-26	Cornell Research Foundation, Inc	Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
CA2135642C (en)	1992-08-21	1999-12-14	James G. Barsoum	Tat-derived transport polypeptides
US6372716B1 (en)	1994-04-26	2002-04-16	Genetics Institute, Inc.	Formulations for factor IX
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
GB9826143D0 (en) *	1998-11-27	1999-01-20	Ludwig Inst Cancer Res	Tumour rejection antigens
US20030118588A1 (en) *	1999-05-22	2003-06-26	Linda Diehl	Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6566329B1 (en)	1999-06-28	2003-05-20	Novo Nordisk A/S	Freeze-dried preparation of human growth hormone
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
EP2009027B1 (en) *	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
US7371849B2 (en)	2001-09-13	2008-05-13	Institute For Antibodies Co., Ltd.	Methods of constructing camel antibody libraries
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
AU2003217912A1 (en) *	2002-03-01	2003-09-16	Xencor	Antibody optimization
US20080199471A1 (en) *	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
WO2005000870A2 (en) *	2003-05-30	2005-01-06	Ludwig Institute Of Cancer Research	Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
WO2005033278A2 (en) *	2003-09-30	2005-04-14	Ludwig Institute For Cancer Research	In vivo efficacy of ny-eso-1 plus iscom
GB0409940D0 (en) *	2004-05-04	2004-06-09	Glaxosmithkline Biolog Sa	Vaccine
NZ579520A (en)	2007-03-13	2012-06-29	Univ Zuerich	Monoclonal human tumor-specific antibody that bnids to ny-eso-1
CA2691089A1 (en)	2007-06-15	2008-12-24	Immurx, Inc.	Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
CN101888856B (zh) *	2007-11-07	2014-08-27	塞尔德克斯医疗公司	结合人树突和上皮细胞205(dec-205)的抗体

2012
- 2012-01-10 PL PL12701463T patent/PL2663580T3/pl unknown
- 2012-01-10 CA CA2821117A patent/CA2821117C/en active Active
- 2012-01-10 CN CN201280004839.1A patent/CN103347898B/zh active Active
- 2012-01-10 JP JP2013547878A patent/JP5828909B2/ja active Active
- 2012-01-10 WO PCT/EP2012/050295 patent/WO2012095412A1/en not_active Ceased
- 2012-01-10 ES ES12701463.7T patent/ES2617983T3/es active Active
- 2012-01-10 US US13/978,995 patent/US20130295091A1/en not_active Abandoned
- 2012-01-10 PT PT127014637T patent/PT2663580T/pt unknown
- 2012-01-10 DK DK12701463.7T patent/DK2663580T3/en active
- 2012-01-10 KR KR1020137017974A patent/KR101614997B1/ko active Active
- 2012-01-10 EP EP12701463.7A patent/EP2663580B1/en active Active
- 2012-01-10 HU HUE12701463A patent/HUE031197T2/en unknown
2013
- 2013-05-30 IL IL226675A patent/IL226675A0/en unknown
2018
- 2018-08-21 US US16/106,500 patent/US20180353603A1/en active Pending

Also Published As

Publication number	Publication date
PT2663580T (pt)	2017-03-10
CA2821117C (en)	2019-02-12
JP5828909B2 (ja)	2015-12-09
JP2014505050A (ja)	2014-02-27
IL226675A0 (en)	2013-07-31
EP2663580B1 (en)	2016-12-07
KR20130114196A (ko)	2013-10-16
US20130295091A1 (en)	2013-11-07
CN103347898B (zh)	2017-12-05
WO2012095412A1 (en)	2012-07-19
ES2617983T3 (es)	2017-06-20
KR101614997B1 (ko)	2016-04-22
CA2821117A1 (en)	2012-07-19
CN103347898A (zh)	2013-10-09
HUE031197T2 (en)	2017-06-28
US20180353603A1 (en)	2018-12-13
EP2663580A1 (en)	2013-11-20
DK2663580T3 (en)	2017-03-13

Publication	Publication Date	Title
IL226675A0 (en)	2013-07-31	Combination therapy that includes antibodies that bind cancer-related antigens
IL282226A (en)	2021-05-31	ST2 antigen-binding proteins
IL229254A0 (en)	2014-01-30	Therapeutic antibodies
IL221288A0 (en)	2012-10-31	Therapeutic methods using anti-cd200 antibodies
IL239339A0 (en)	2015-07-30	Therapeutic 47cd antibodies
PL2665749T3 (pl)	2016-06-30	Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
SG10201501784YA (en)	2015-05-28	Methods for enhancing anti-tumor antibody therapy
IL230553A0 (en)	2014-03-31	Bispecific antigen binding molecules
PH12014500666A1 (en)	2014-05-26	Cd27l antigen binding proteins
ZA201303734B (en)	2016-02-24	Multispecific antigen binding proteins targeting hgf
IL266452B (en)	2020-10-29	Antibodies against kidney-associated antigen-1, and their antigen-binding fragments
IL226157A0 (en)	2013-06-27	Antigen binding proteins
SG10201508535RA (en)	2015-11-27	Antigen Presenting Cancer Vaccine
GB201106630D0 (en)	2011-06-01	Cancer therapy
ZA201308992B (en)	2021-05-26	Therapeutic antibodies
GB201118220D0 (en)	2011-12-07	Cancer therapy